Business ❯ Pharmaceuticals

Acquisitions

Drug Development Sanofi Corporate Strategy Merck Biotechnology Mergers and Acquisitions Novartis Biopharmaceuticals Eli Lilly Oncology Novo Nordisk Pfizer Merck & Co. AbbVie Rare Diseases Market Trends Bristol Myers Squibb Market Strategy Vertex Pharmaceuticals Biotech Companies Immunology BioNTech Vaccine Development Clinical Development Gene Therapy Market Dynamics Corporate Finance Cancer Treatment Market Competition Genmab AstraZeneca PLC Intellectual Property Strategic Partnerships Regulatory Approval Data Privacy Private Equity Partnerships Competition Moderna Mergers COVID-19 Impact Merus International Expansion Generic Drugs Biontech Angelini Pharma Cancer Treatments Merck Group Market Expansion Genetic Medicine Zydus Lifesciences Ophthalmology Psychedelic Drugs JB Chemicals Organon & Co GSK Strategic Planning Evotec Biopharmaceutical Companies Biotech Company History Psychedelic Treatments Icosavax Acquisition Psychedelic Therapies Weight Loss Drugs Genetic Testing AstraZeneca Vaccine Industry Icosavax Obesity Drugs Teva Pharmaceuticals Biopharma Industry Neuroscience Corporate Transactions Market Valuation First Wave BioPharma Inc Gilead Sciences Biopharma Clinical Trials Genetics Obesity Treatments Biogen Financial Impact

Lilly to Acquire AtaiBeckley in Deal Valued Up to $3.8 Billion

The purchase puts a Breakthrough‑designated intranasal 5‑MeO‑DMT into Lilly's neuroscience portfolio, potentially speeding its development.

Eli Lilly Agrees to Buy Psychedelic Biotech AtaiBeckley for $2.8 Billion

Vertex to Buy Crinetics for $10 Billion, Gaining Oral Endocrine Drugs

GSK to Buy Nuvalent for $10.6 Billion to Bolster Lung‑Cancer Pipeline

Lilly Agrees to Buy Three Vaccine Developers for Up to $3.8 Billion

Lilly Acquires Engage Biologics for Up to $202 Million

UCB to Buy Candid Therapeutics for Up to $2.2 Billion

LEO Pharma to Acquire Replay in $50 Million Gene-Therapy Deal

Lilly to Acquire Ajax Therapeutics in Up to $2.3 Billion Blood Cancer Deal

Eli Lilly to Buy Kelonia for Up to $7 Billion to Gain In‑Vivo CAR‑T Platform

Lilly to Acquire Centessa for $6.3 Billion to Add Orexin Sleep Drugs

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Pfizer’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug